UiPath's pivot to a model-agnostic process orchestration platform positions it to capture enterprise AI spend, supported by accelerating AI ARR and management's re-acceleration plan.
Structural headwinds from AI pricing compression and competition undermine PATH's ability to achieve sustained re-acceleration, raising estimate risk and capping multiple.
D.A. Davidson downgraded the stock due to increasing resistance to AI pricing and the emergence of cheaper agent alternatives, clouding ARR acceleration.
The firm sees risk to 4Q ARR and slower FY28 growth despite AI products representing a significant portion of 1H FY27 NARR.
UBS noted that early renewals and intra-contract upsell are improving.
Coding Agents could accelerate the conversion of existing automation backlogs into production and potentially reaccelerate revenue/ARR growth, though still early.
UBS maintained a Neutral rating and cut its price target to $15 from $19 due to a lower peer-group multiple.
Citi initiated coverage with a Buy rating and a $23 price target, seeing UiPath evolving from RPA into an enterprise AI control plane.
Citi believes UiPath’s deterministic automation layer plus Maestro orchestration should become more valuable as enterprises deploy fragmented fleets of agents, models, humans, and APIs, positioning PATH as a model-agnostic control plane.
Citi sees FY27 AI ARR reaching ~$325M, +63% y/y, and models ~12%+ ARR CAGR through FY30 versus consensus around ~8–9%, with FY27/28 estimates 150–300bps above Street.
Citi also sees outcome-based pricing and growing AI attachment as incremental monetization levers, with the Sept. 22 Investor Day as the next major catalyst.
Outgoing CFO and new COO Ashim Gupta stated that stabilization is proven and re-acceleration is the plan, indicating confidence in future growth.
Management is not satisfied with 12.5% growth, implying a commitment to higher growth rates.
The company differentiates itself by selling business-process orchestration across various components, while competitors sell agentic orchestration, highlighting a unique value proposition.
Frontier labs can generate code but cannot run a process end to end, suggesting a need for PATH's comprehensive solutions.
Outcome-based pricing is progressing through forward-deployed engineers, indicating a flexible and customer-centric pricing model.
On-premise solutions are becoming a topic of discussion again due to security and sovereignty concerns, potentially benefiting PATH's offerings.
The stock declined following through on computer use Astra fears, indicating market concerns about the impact of new AI technologies.
Research through 2026-09-30 · 2026-09-08 to 2026-09-30 · 4 source reports.
| Range | Prices through |
|---|---|
| 1W | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | |
| 2Y | |
| 3Y |
Research through 2026-11-03. Artifact validity does not establish factual accuracy or research freshness.